Literature DB >> 9416458

The influence of established and new antiepileptic drugs on visual perception. 1. A placebo-controlled, double-blind, single-dose study in healthy volunteers.

B J Steinhoff1, N Freudenthaler, W Paulus.   

Abstract

The influence of single oral dosages of carbamazepine (CBZ), valproic acid, vigabatrin (VGB), lamotrigine (LTG), gabapentin (GBP), and losigamone (LSG) on visual perception was investigated in ten healthy volunteers according to a double-blind, placebo-controlled, cross-over study design. The test battery comprised visual acuity, the Lanthony-D-15-désaturé colour perception test, increment, postadaptation and transient tritanopia threshold measurements, perception threshold assessment for monochromatic and chromatic gaussian dots, monochromatic gratings and gratings of differing spatial frequency, and critical flicker fusion tests with various stimuli. The only consistent and partly significant effects were seen after VGB and GBP. After VGB, increment, postadaptation and transient tritanopia thresholds and the critical flicker fusion increased, whereas GBP led to a somewhat converse profile. The other tests were not influenced consistently by any antiepileptic drug (AED). We conclude that: (i) gamma-amino-butyric acid-(GABA)-related properties as under the prototype drug VGB result in specific alterations of the transient tritanopia phenomenon which is consistent with the physiological hypothesis for this retinal paradigm based on extracellular recordings in primates. The possible mechanisms why VGB improved critical flicker fusion as the only AED in this trial are discussed. The profile of GBP indicates a unique mechanism of action. We have not observed specific influences on visual perception under AEDs which act mainly via alterations of ion membrane conductance. The transient tritanopia and flicker fusion paradigms we used appear to be promising to investigate antiepileptic drugs with hitherto unknown modes of actions in human noninvasively.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9416458     DOI: 10.1016/s0920-1211(97)00060-0

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  10 in total

1.  Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers.

Authors:  I Nousiainen; R Kälviäinen; M Mäntyjärvi
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

2.  Retinal function and histopathology in rabbits treated with Topiramate.

Authors:  S Kjellström; A Bruun; B Isaksson; T Eriksson; S Andréasson; V Ponjavic
Journal:  Doc Ophthalmol       Date:  2006-11-18       Impact factor: 2.379

Review 3.  Ocular adverse effects of common psychotropic agents: a review.

Authors:  Sami Richa; Jean-Claude Yazbek
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

4.  Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.

Authors:  Wynne K Schiffer; Douglas Marsteller; Stephen L Dewey
Journal:  Psychopharmacology (Berl)       Date:  2003-04-09       Impact factor: 4.530

5.  Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.

Authors:  V Ponjavic; S Andréasson
Journal:  Doc Ophthalmol       Date:  2001-01       Impact factor: 2.379

Review 6.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

7.  Alterations in electroretinograms and retinal morphology in rabbits treated with vigabatrin.

Authors:  Vesna Ponjavic; Lotta Gränse; Sten Kjellström; Sten Andréasson; Anitha Bruun
Journal:  Doc Ophthalmol       Date:  2004-03       Impact factor: 2.379

8.  Color vision deficiency in preschool children: the multi-ethnic pediatric eye disease study.

Authors:  John Z Xie; Kristina Tarczy-Hornoch; Jesse Lin; Susan A Cotter; Mina Torres; Rohit Varma
Journal:  Ophthalmology       Date:  2014-03-16       Impact factor: 12.079

Review 9.  Visual field defects with vigabatrin: epidemiology and therapeutic implications.

Authors:  R Kälviäinen; I Nousiainen
Journal:  CNS Drugs       Date:  2001       Impact factor: 6.497

10.  Macular Edema after Gabapentin.

Authors:  Ju Young Kim; Don Gyung Kim; Soo Han Kim; Oh Woong Kwon; Soon Hyun Kim; Yong Sung You
Journal:  Korean J Ophthalmol       Date:  2016-03-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.